Lexicon Pharmaceuticals (LXRX) Fundamental Analysis: Revenue, Earnings & Valuation

7.21 / 10

Outperform

Fundamental analysis rates LXRX as Outperform with a 7.2/10 score. Revenue‑to‑MV and Cash‑to‑MV are bullish, contributing positively, while Fixed‑asset turnover and Income‑tax‑to‑profit are weaker. YoY revenue growth exceeds 60%, inventory turnover is efficient, and cost‑of‑sales ratio remains low, supporting a favorable outlook.

Analysis Checks(6/10)

Revenue-MV

Value-2.52

Score2/3

Weight32.98%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value60.24

Score3/3

Weight5.24%

1M Return1.54%

Inventory turnover ratio

Value1.07

Score2/3

Weight-3.78%

1M Return-1.21%

Gross profit margin (%)

Value99.45

Score0/3

Weight-19.67%

1M Return-7.24%

PB-ROE

Value1.19

Score1/3

Weight22.52%

1M Return5.29%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-1.55%

1M Return-0.50%

Fixed assets turnover ratio

Value6.04

Score1/3

Weight-3.75%

1M Return-1.24%

Cost of sales ratio (%)

Value0.55

Score2/3

Weight-12.91%

1M Return-4.42%

Asset-MV

Value-0.55

Score3/3

Weight57.06%

1M Return11.84%

Cash-MV

Value0.02

Score2/3

Weight23.88%

1M Return5.94%

Is LXRX undervalued or overvalued?

LXRX scores 7.21/10 on fundamentals and holds a Discounted valuation at present. Backed by its -39.72% ROE, -101.08% net margin, -13.13 P/E ratio, 6.15 P/B ratio, and 77.78% earnings growth, these metrics solidify its Outperform investment rating.